Health Care • Biotechnology: Pharmaceutical Preparations
$26.86 ▲ +1.50
(+5.92%)
MKT CAP: $3.38B • VOL: 6.75M
52W L $24 52W H $43
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$23
MEDIAN
$30
MEAN
$31
HIGH
$37
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE VKTX TAPE
VKTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $32.50 | $30.89 | 2025-02-14 | $24.44 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $33.84 | $31.69 | 2025-02-06 | $25.25 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $30.62 | $29.55 | 2025-01-29 | $25.79 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $27.40 | — | 2025-01-17 | $26.32 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $23.64 | $25.52 | 2025-01-09 | $23.91 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $31.96 | $27.93 | 2024-12-18 | $23.37 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $26.05 | $27.13 | 2024-12-04 | $24.98 | -4.3% | 48% | C |